Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
December 15, 2023 01:15 ET
|
F. Hoffmann-La Roche Ltd
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices The ranking acknowledges Roche’s commitment to sustainability as an integral part of its...
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
December 11, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of...
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
December 09, 2023 11:30 ET
|
F. Hoffmann-La Roche Ltd
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years...
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
December 08, 2023 11:50 ET
|
F. Hoffmann-La Roche Ltd
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive...
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
December 08, 2023 11:45 ET
|
F. Hoffmann-La Roche Ltd
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to...
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
December 05, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in...
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
December 04, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with...
Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
November 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Elecsys® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory...
Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List
November 16, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
It is estimated that one third of the global population could be at risk for infection with Hepatitis E virus.1The new tests allow clinicians to diagnose acute and chronic infections amongst patients...
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
November 14, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all...